Nicolás Isambert

Centre Hospitalier Universitaire de Poitiers — France

Medicine · Health Sciences

61h-index14.1kcitations444works6.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(134), Vascular Tumors and Angiosarcomas(52), Lung Cancer Treatments and Mutations(50), Gastrointestinal Tumor Research and Treatment(44), Cancer Treatment and Pharmacology(44)

Publications440 total

Abstract PS5-01-22: Efficacy of second- or third-line Tucatinib, Trastuzumab, and Capecitabine (TTC) following trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer: A multicenter French cohort study
Clinical Cancer Research·2026
Abstract PD3-08: Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: results from International, retrospective, real-world ADC-Low-Europe cohort
Clinical Cancer Research·2026
Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted clinical trials: a retrospective cohort analysis
Clinical & Translational Oncology·2025Open Access
Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)”
Annals of Oncology·2025
Selection of Criteria in the Diagnosis Approach of Paraneoplastic Fever in Adults With Solid Neoplasia Using a Delphi Method
Cancer Investigation·2025
What are the sociodemographic characteristics of lung cancer patients travelling far to get surgery?
Bulletin du Cancer·2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Journal of Clinical Oncology·2025· 5 cited
LBA98 Final results of the RAR-IMMUNE study: A randomized, comparative, prospective, multicenter phase III trial of the efficacy of nivolumab + ipilimumab (N+I) versus pazopanib (P) in patients (pt) with advanced sarcoma (S) of rare subtype
Annals of Oncology·2025Open Access
Représentativité des patients atteints de cancer du poumon : différences entre un registre de cancer populationnel et un centre hospitalier universitaire
Bulletin du Cancer·2025
PROPAN: Bayesian dose-finding of propranolol combined with metronomic fixed-dose cyclophosphamide based on bivariate efficacy-tolerability outcomes in patients with locally advanced or metastatic angiosarcoma (LAMA): A phase I-II sequential trial by the French Sarcoma Group.
Journal of Clinical Oncology·2025
CO9.2 - Bayesian model using bivariate efficacy-tolerability outcome in patients with angiosarcoma to determine the safe most successful dose of propranolol in combination with metronomic fixed-dose cyclophosphamide: PROPAN a Phase I-II sequential trial
Journal of Epidemiology and Population Health·2025
Abstract CT129: Immunity induction with atezolizumab, EIK1001, and radiotherapy in virus-associated tumors: Results of the AGADIR Trial
Cancer Research·2025
Small Extracellular Vesicles as Biomarkers in Sarcoma Follow-Up: Protocol for a Prospective, Multicentric Pilot Study
JMIR Research Protocols·2025· 1 citedOpen Access
Doxorubicin-Trabectedin With Trabectedin Maintenance in Leiomyosarcoma
Obstetrical & Gynecological Survey·2025
Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SArcoma MAnagement – OSAMA Study)
International Journal of Gynecological Cancer·2025· 1 citedOpen Access
Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC
JTO Clinical and Research Reports·2024Open Access
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
New England Journal of Medicine·2024· 69 citedOpen Access
1311P Phase II, open-label study of frontline tusamitamab ravtansine with pembrolizumab ± chemotherapy in advanced non-squamous non-small cell lung cancer: Updated results from CARMEN-LC05 trial
Annals of Oncology·2024· 5 citedOpen Access
1719O Multisarc: A randomized precision medicine study in advanced soft-tissue sarcomas
Annals of Oncology·2024· 2 citedOpen Access
Small Extracellular Vesicles as Biomarkers in Sarcoma Follow-Up: Protocol for a Prospective, Multicentric Pilot Study (Preprint)
2024Open Access
page 1 of 22Next →

Frequent Co-authors

Nicolas Penel(28), Jean‐Yves Blay(28), Antoîne Italiano(26), Emmanuelle Bompas(25), Sophie Piperno‐Neumann(19), Christine Chevreau(19), François Bertucci(19), Florence Duffaud(13), Isabelle Ray‐Coquard(12), Axel Le Cesne(11), Corinne Delcambre(11), Axel Le Cesne(11), Didier Cupissol(10), Olivier Collard(10), Sylvie Bonvalot(8), Cécile Guillemet(8), María Rios(7), Isabelle Ray‐Coquard(7), L. Chaigneau(7), Sébastien Salas(7)